BridgeBio Pharma (BBIO) said Thursday that the Japanese Ministry of Health, Labor and Welfare has approved acoramidis, under the brand name Beyonttra, to treat adults with transthyretin-mediated amyloid cardiomyopathy, a heart condition caused by abnormal deposits of the transthyretin protein in the heart muscle.
The biopharmaceutical company said the approval is based on results from a phase 3 study conducted in Japan in which acoramidis was generally well tolerated and had a 0% mortality rate during a 30-month treatment period.
Shares were 0.9% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。